CD274 and non-small cell lung carcinoma: Atezolizumab, a monoclonal antibody against programmed death ligand-1 (PD-L1), has shown highly promising outcomes in enhancing survival rates in patients with metastatic lung cancer with EGFR or ALK aberrations and PD-L1 expression, as well as in resected patients diagnosed with stage II or IIIA NSCLC [114].